drugset / Trial / NCT00291668
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
Timeline
- Start
- 2006-03-02
- Primary completion
- 2007-11-08
- Completion
- 2007-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | Subcutaneous |
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 400 mg | Subcutaneous |